• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Vaxcyte Inc.

    3/5/25 4:10:42 PM ET
    $PCVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PCVX alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001918033
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Vaxcyte, Inc.
    SEC File Number
    001-39323
    Address of Issuer
    825 INDUSTRIAL ROAD, STE. 300
    SAN CARLOS
    CALIFORNIA
    94070
    Phone
    650-837-0111
    Name of Person for Whose Account the Securities are To Be Sold
    Eydelman Mikhail
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    UBS Financial Services, Inc.
    1000 Harbor Blvd
    3rd Floor
    Weehawken � NJ � 07086
    5000344350.0012876162203/05/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common03/05/2025Exercise of stock optionsIssuerCheckbox not checked500003/05/2025CASH

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Mikhail Eydelman
    825 INDUSTRIAL ROAD
    STE. 300
    San Carlos � CA � 94070
    Common02/05/20255000450369.00
    Mikhail Eydelman
    825 INDUSTRIAL ROAD
    STE. 300
    San Carlos � CA � 94070
    Common12/05/20245000457434.50
    Mikhail Eydelman
    825 INDUSTRIAL ROAD, STE. 300
    San Carlos � CA � 94070
    Common01/06/20255000427921.50

    144: Remarks and Signature

    Remarks
    Date of Notice
    03/05/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    06/11/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ UBS Financial Services Inc, as attorney-in-fact for Mikhail Eydelman

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $PCVX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PCVX

    DatePrice TargetRatingAnalyst
    4/22/2025Overweight
    Cantor Fitzgerald
    12/20/2024$135.00Buy
    Goldman
    12/7/2023$69.00Buy
    Mizuho
    4/18/2023Outperform
    TD Cowen
    1/3/2023$52.00 → $58.00Buy
    Needham
    12/15/2022$66.00Buy
    Guggenheim
    11/17/2022$69.00Buy
    BTIG Research
    12/29/2021$50.00Buy
    Jefferies
    More analyst ratings

    $PCVX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update

      -- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 2 Dose-Finding Study of VAX-24 in Healthy Infants; Balance of Data Expected by End of 2025 -- -- Initiated Second and Final Stage of VAX-31 Infant Phase 2 Dose-Finding Study; Topline Safety, Tolerability and Immunogenicity Data from Primary Three-Dose Immunization Series Expected in Mid-2026, With Complete Booster Data Up to Nine Months Later -- -- Company Expects to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 -- -- Announced VAX-XL, Third-Generation Pneumococcal Conjugate Vaccine Candidate Desig

      5/7/25 4:01:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

      SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.

      5/1/25 8:00:29 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

      -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu

      3/31/25 7:00:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Brandicourt Olivier

      4 - Vaxcyte, Inc. (0001649094) (Issuer)

      5/2/25 4:28:47 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Brandicourt Olivier claimed no ownership of stock in the company (SEC Form 3)

      3 - Vaxcyte, Inc. (0001649094) (Issuer)

      5/2/25 4:27:02 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Dhaliwal Harpreet S. claimed ownership of 36,083 shares (SEC Form 3)

      3 - Vaxcyte, Inc. (0001649094) (Issuer)

      4/25/25 4:13:50 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Leadership Updates

    Live Leadership Updates

    See more
    • Vaxcyte Appoints Dr. Olivier Brandicourt to Board of Directors

      SAN CARLOS, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed Dr. Olivier Brandicourt, a veteran biopharmaceutical industry executive and the former Chief Executive Officer of Sanofi S.A., to its Board of Directors. "We are thrilled to welcome Olivier to Vaxcyte's Board of Directors," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "He brings a wealth of biopharmaceutical expertise, with significant experience in commercial strategy and execution within the global vaccine market.

      5/1/25 8:00:29 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints John Furey to Board of Directors

      SAN CARLOS, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it has appointed John Furey, a seasoned industry expert, to its Board of Directors. "We are thrilled to welcome John to Vaxcyte's Board of Directors and look forward to benefiting from his wealth of biopharmaceutical and vaccine expertise, including the manufacture, supply and commercialization of pneumococcal conjugate vaccines (PCVs)," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "As we continue to progress our PCV candidates, VAX-24

      7/2/24 8:30:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Appoints Whitney Jones as Chief People Officer

      -- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the appointment of Whitney Jones as Chief People Officer. Ms. Jones will lead Vaxcyte's human resources strategy and operations, including people and culture, talent acquisition and management, learning and development, total rewards and employee engagement. "At Vaxcyte, we are proud to cultivate a culture that values coll

      1/16/24 4:01:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $PCVX
    SEC Filings

    See more

    $PCVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/14/24 5:46:11 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/14/24 2:53:06 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Vaxcyte Inc.

      SC 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      11/12/24 10:34:18 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Vaxcyte Inc.

      SCHEDULE 13G/A - Vaxcyte, Inc. (0001649094) (Subject)

      5/15/25 4:51:54 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Vaxcyte Inc.

      10-Q - Vaxcyte, Inc. (0001649094) (Filer)

      5/7/25 4:23:38 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vaxcyte, Inc. (0001649094) (Filer)

      5/7/25 4:03:56 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Vaxcyte

      Cantor Fitzgerald initiated coverage of Vaxcyte with a rating of Overweight

      4/22/25 7:35:12 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Vaxcyte with a new price target

      Goldman initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $135.00

      12/20/24 7:47:04 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho initiated coverage on Vaxcyte with a new price target

      Mizuho initiated coverage of Vaxcyte with a rating of Buy and set a new price target of $69.00

      12/7/23 7:01:04 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PCVX
    Financials

    Live finance-specific insights

    See more
    • Vaxcyte Announces Positive Topline Results from VAX-24 Infant Phase 2 Dose-Finding Study

      -- At All Doses Evaluated, VAX-24 Was Well-Tolerated and Demonstrated a Safety and Tolerability Profile Similar to Prevnar 20® (PCV20) -- -- At All Doses Evaluated, VAX-24 Elicited Substantial Immune Responses Following Primary Three-Dose Immunization Series; Topline Results Also Include Interim Booster Dose IgG Data Showing Robust Memory Responses Across All Doses -- -- Dose-Dependent Immune Responses Consistently Demonstrated and Little to No Evidence of Carrier Suppression Was Observed, Supporting Platform's Potential to Deliver Broadest-Spectrum Infant Pneumococcal Conjugate Vaccine (PCV) Candidates -- -- Company Selects VAX-24 Mid Dose (2.2mcg) as Basis for Optimized Dose Formu

      3/31/25 7:00:00 AM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte to Host Webcast and Conference Call to Present Topline Results from VAX-24 Infant Phase 2 Study

      SAN CARLOS, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced it will hold a webcast and conference call tomorrow, March 31, 2025, at 8:00 a.m. Eastern Time to present topline results from the VAX-24 infant Phase 2 study. This study is evaluating the safety, tolerability and immunogenicity of VAX-24, the Company's 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® in healthy infants. To participate in the conference call, p

      3/30/25 5:00:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vaxcyte to Report Fourth Quarter and Full Year 2024 Financial Results on February 25, 2025

      SAN CARLOS, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (NASDAQ:PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it will report financial results for the fourth quarter and full year 2024 after market close on February 25, 2025. Company management will host a conference call and webcast beginning at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a business update. To participate in the conference call, please dial 800-225-9448 (domestic) or 203-518-9708 (international) and refer to conference ID PCVXQ424. A live webcast

      2/12/25 4:05:00 PM ET
      $PCVX
      Biotechnology: Pharmaceutical Preparations
      Health Care